Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow RVTY
Revvity Inc. (RVTY) EBITDA
Revvity Inc.'s EBITDA for fiscal 2025 was $766.5M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $775.8M. Over the past ten years it has ranged from $365.1M (fiscal 2015) to $1.6B (fiscal 2021); the current reading is higher than 64% of that period. Revvity Inc. ranks 11th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $766.5M | (1.81%) |
| FY2024 | $780.7M | 5.54% |
| FY2023 | $739.7M | (39.48%) |
| FY2022 | $1.2B | (24.08%) |
| FY2021 | $1.6B | 49.89% |
| FY2020 | $1.1B | 78.60% |
| FY2019 | $601.4M | 14.11% |
| FY2018 | $527.1M | 28.75% |
| FY2017 | $409.4M | 3.10% |
| FY2016 | $397.1M | 8.77% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $192.7M | 5.81% |
| Mar 2026 | $182.1M | (15.63%) |
| Dec 2025 | $215.8M | 16.54% |
| Sep 2025 | $185.2M | (4.91%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| RVTY Revvity Inc. | $775.8M |
| ICLR ICON PLC compare | $666.9M |
| QGEN QIAGEN N.V. compare | $651.0M |
| MEDP Medpace Holdings, Inc. compare | $611.2M |
| CRL Charles River Laboratories International, Inc. compare | $553.0M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| GH Guardant Health, Inc. compare | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RVTY
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement